Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

References

• MS: The BasicsRocky Mountain MS Center Available from: http://www.mscenter.org/education/ms-the-basics/Accessed Jun 24, 2010
   Google Scholar
• JaniecKWajgtAKondera-AnaszZEffect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosisMed Sci Monit200171939811208501
   PubMedGoogle Scholar
• Novantrone [Package insert]Rockland, MASerono, Inc2009
   Google Scholar
• The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosisNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• PRISMS Study GroupRandomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Engl J Med20003431389890411006365
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDSFrancisGRandomized, comparative study of interferon β-1a treatment regimens in MSNeurology2002591496150612451188
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet200235993161453146011988242
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosisNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 mcg or 500 mcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomized, multicentre studyLancet Neurol2009888989719729344
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open- label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med200635491192316510745
   PubMed Web of Science ®Google Scholar
• Tysabri [Package insert]Cambridge, MABiogen, Inc2009
   Google Scholar
• RioJNosCTintoreMDefining the response to interferon-β in relapsing-remitting multiple sclerosis patientsAnn Neurol200659234435216437558
   PubMed Web of Science ®Google Scholar
• LeistTPVermerschPThe potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulationCurr Med Res Opin200723112667267617880754
   PubMed Web of Science ®Google Scholar
• SipeJCCladribine for multiple sclerosis: Review and current statusExpert Rev Neurother20055672172716274330
   PubMedGoogle Scholar
• BeutlerECladribine (2-chlorodeoxyadenosine)Lancet199234088259529561357355
   PubMed Web of Science ®Google Scholar
• KopadzeTDobertMLeussinkVIDehmelTKieseierBCCladribine impedes in vitro migration of mononuclear cells: A possible implication for treating multiple sclerosisEur J Neurol200916340941219175384
   PubMed Web of Science ®Google Scholar
• LiliemarkJJuliussonGOn the pharmacokinetics of 2-chloro-2’-deoxyadenosine in humansCancer Res19915120557055721680554
   PubMed Web of Science ®Google Scholar
• LiliemarkJThe clinical pharmacokinetics of cladribineClin Pharmacokinet19973221201319068927
   PubMed Web of Science ®Google Scholar
• KearnsCMBlakleyRLSantanaVMCromWRPharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemiaCancer Res1994545123512397906999
   PubMed Web of Science ®Google Scholar
• LiliemarkJAlbertioniFHassanMJuliussonGOn the bioavailability of oral and subcutaneous 2-chloro-2’-deoxyadenosine in humans: Alternative routes of administrationJ Clin Oncol19921010151415181357107
   PubMed Web of Science ®Google Scholar
• AlbertioniFJuliussonGLiliemarkJOn the bioavailability of 2-chloro- 2’-deoxyadenosine (CdA). The influence of food and omeprazoleEur J Clin Pharmacol19934465795828104793
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med2010362541642620089960
   PubMed Web of Science ®Google Scholar
• Clarity extension study Available from: http://www.clinicaltrials.gov/ct2/show/NCT00641537Accessed Jul 22, 2010
   Google Scholar
• Phase II cladribine add-on to interferon-beta (IFN-b) therapy in MS subjects with active disease (ONWARD) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00436826Accessed Apr 1, 2010
   Google Scholar
• Oral cladribine in early multiple sclerosis (MS) (ORACLE MS) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00725985Accessed Apr 1, 2010
   Google Scholar
• SipeJCCladribine tablets: A potential new short-course annual treatment for relapsing multiple sclerosisExpert Rev Neurother201010336537520187859
   PubMed Web of Science ®Google Scholar
• Leustatin [Package insert]Raritan, NJOrtho Biotech Products, L.P.2007
   Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• CohenBARieckmannPEmerging oral therapies for multiple sclerosisInt J Clin Pract200761111922193017784852
   PubMed Web of Science ®Google Scholar
• Cladribine (Mylinax)The Multiple Sclerosis Resource Centre Available from: http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1629Accessed Jun 29, 2010
   Google Scholar